KW-7158
| Code | Size | Price |
|---|
| TAR-T27758-5mg | 5mg | £1,010.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27758-50mg | 50mg | £1,982.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27758-100mg | 100mg | £2,560.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
KW-7158, a potassium channel activator, is used potentially for the treatment of urinary urgency and frequency.
CAS:
214764-26-8
Formula:
C16H12F3NO5S2
Molecular Weight:
419.39
Purity:
0.98
SMILES:
C[C@](O)(C(=O)Nc1cccc2c1C(=O)c1sccc1CS2(=O)=O)C(F)(F)F
References
1. Nishiya Y, Yamagata T, Fukuda A, Yokokawa S, Seishi T, Sakuma T, Sasho S, Shimizu Y, Sato H, Sekine S, Kamigaki M, Yoshida T, Shibata K. The anti-overactive bladder activity of KW-7158 is mediated by blocking equilibrative nucleoside transporter-1. Biol Pharm Bull. 2014;37(1):130-6. PubMed PMID: 24162843.
2. Maeda H, Fujita K, Kobayashi H, Ushiki J, Nakanishi T, Tamai I. Novel LC-MS/MS method for simultaneous quantification of KW-7158, a new drug candidate for urinary incontinence and bladder hyperactivity, and its metabolites in rat plasma: a pharmacokinetic study in male and female rats. Arzneimittelforschung. 2012 May;62(5):213-21. doi: 10.1055/s-0032-1301883. PubMed PMID: 22344572.
3. Maeda H, Kodaira H, Fujita K, Kobayashi H, Ushiki J, Nakanishi T, Tamai I. Species differences in the pharmacokinetics of KW-7158 [(2S)-(+)-3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[ 3,2-c][1]benzothiepin-9-yl)propanamide]: formation of hydrolyzed metabolite in human and animals. Xenobiotica. 2012 Jul;42(7):649-59. doi: 10.3109/00498254.2011.652993. PubMed PMID: 22324379.
4. Nishiya Y, Yokokawa S, Fukuda A, Yamagata T, Inayoshi A, Obinata M, Shibata K. The generation of rat dorsal root ganglion cell lines to identify the target of KW-7158, a novel treatment for overactive bladder. Neurosci Res. 2011 Nov;71(3):278-88. doi: 10.1016/j.neures.2011.07.1823. PubMed PMID: 21802454.